Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6976999 | 1.00 | IRAK4 (0.34) | IRAK4CNR2 | |
| SCHEMBL9975285 | 0.84 | IRAK4 (0.39) | IRAK4 | |
| SCHEMBL9975260 | 0.84 | IRAK4 (0.39) | IRAK4 | |
| SCHEMBL14548690 | 0.83 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL6978053 | 0.83 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL14878204 | 0.82 | IRAK4 (0.31) | IRAK4 | |
| SCHEMBL14878201 | 0.82 | IRAK4 (0.31) | IRAK4 | |
| SCHEMBL15304826 | 0.78 | — | — | |
| SCHEMBL6956713 | 0.76 | IRAK4 (0.34) | IRAK4 | |
| SCHEMBL6958666 | 0.76 | IRAK4 (0.34) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20110257391-A1 | PROCESS FOR PRODUCTION OF QUINAZOLINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257391-A1 | PROCESS FOR PRODUCTION OF QUINAZOLINE DERIVATIVE | ABL1, MAP2K5, MAP2K2 | IRAK4 690/4885CNR2 1209/4885 |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | IRAK4 1421/4885CNR2 491/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | IRAK4 1421/4885CNR2 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.